ADM-NH2 Biomarker Stratification for Corticosteroid Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet medical need to stratify critically ill patients for treatment with corticosteroids, particularly in conditions such as sepsis, septic shock, COVID-19, and acute respiratory distress syndrome (ARDS), as existing methods lack effective biomarkers to guide the use of corticosteroids, leading to variable treatment outcomes and potential side effects.
Innovation Solution
A method involving the determination of ADM-NH2 or its fragments in bodily fluids, comparing the levels to pre-determined thresholds to decide on the initiation or cessation of corticosteroid therapy, using capture binders and immunoassays to quantify ADM-NH2 levels accurately.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If corticosteroid therapy is administered to all critically ill patients, then some patients may benefit from reduced inflammation and improved outcomes, but many patients will receive unnecessary treatment exposing them to potential side effects and increasing healthcare costs
Solution Approach 1:
The patent applies local quality by differentiating treatment based on patient subgroups defined by ADM-NH2 biomarker levels. Instead of uniform treatment, patients are stratified into those with high ADM-NH2 levels (who benefit from corticosteroids) and those with low levels (who do not benefit), allowing tailored therapy that maximizes efficacy while minimizing harm to each specific patient group
Solution Approach 2:
The patent utilizes parameter changes by measuring the ADM-NH2 biomarker level as a threshold parameter to determine treatment eligibility. By establishing a specific concentration threshold (e.g., above or below a predetermined level), the system objectively transitions patients between treatment and no-treatment states, eliminating subjective decision-making and ensuring consistent application of the stratification criterion
2Object-affected harmful factors
If corticosteroid therapy is avoided in patients with low ADM-NH2 levels, then unnecessary side effects are prevented, but the ability to identify beneficiaries of treatment is lost without effective biomarkers
Solution Approach 1:
The patent introduces an intermediary biomarker (ADM-NH2) that mediates between the patient's physiological state and the treatment decision. This intermediary provides objective, measurable information about the patient's response to endotoxin challenge, serving as a proxy for identifying those who will benefit from corticosteroid therapy without requiring direct observation of complex inflammatory responses
Solution Approach 2:
The patent replaces the mechanical/clinical system of trial-and-error treatment or empirical decision-making with a biochemical measurement system. By substituting direct clinical observation and empirical treatment protocols with an in vitro biomarker assay, the system provides more reliable, objective, and standardized treatment guidance that can be consistently applied across different clinical settings
3Ease of operation
If existing biomarkers are used to guide corticosteroid therapy, then treatment decisions can be made, but the biomarkers lack the precision and reliability needed for effective patient stratification
Solution Approach 1:
The patent creates a simplified copy or model of the complex inflammatory response by measuring ADM-NH2 levels in response to endotoxin challenge. Rather than attempting to measure multiple complex inflammatory parameters simultaneously, the system uses a single biomarker that replicates the essential information needed for treatment decision-making, providing a reliable proxy for the underlying physiological state
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables precise stratification of patients, potentially preventing septic shock, reducing hospital stay, and improving outcomes by tailoring corticosteroid treatment based on individual ADM-NH2 levels, thereby optimizing therapy and minimizing adverse effects.
Implementation Method 1
determining the level of ADM-NH2 or fragment thereof in a sample of bodily fluid of said patient
Data Source
AI summary
A method of selecting critically ill patients for treatment with corticosteroids, by determining the level of ADM-NH2 or fragment thereof in a sample of bodily fluid of the patient, comparing the level of ADM-NH2 or fragment thereof to a pre-determined threshold or to a previously measured level of ADM-NH2 or fragment thereof, and at a value above the threshold appointing a therapy with corticosteroids. A method for corticosteroid therapy guidance and/or stratification in critically ill patients by providing a sample of bodily fluid of the patient, and determining the level of ADM-NH2 or fragment thereof in the sample, and comparing the level of ADM-NH2 or fragment thereof to a pre-determined threshold or to a previously measured level of ADM-NH2 or fragment thereof, wherein the level of ADM-NH2 or fragments thereof is indicative of whether an initiation of a corticosteroid therapy is required.